ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140
,2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1
,2010, 'MS544 CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', Atherosclerosis Supplements, 11, pp. 219 - 219, http://dx.doi.org/10.1016/s1567-5688(10)71044-8
,2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3
,